Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 166,800 shares, a decline of 44.4% from the May 15th total of 300,100 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily volume of 766,700 shares, the days-to-cover ratio is currently 0.2 days.
Wall Street Analyst Weigh In
RBGLY has been the subject of a number of analyst reports. Sanford C. Bernstein raised shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Royal Bank Of Canada reissued an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy".
View Our Latest Report on RBGLY
Reckitt Benckiser Group Stock Performance
Shares of Reckitt Benckiser Group stock traded up $0.14 on Wednesday, reaching $13.95. 425,810 shares of the company were exchanged, compared to its average volume of 380,547. The company has a current ratio of 0.58, a quick ratio of 0.39 and a debt-to-equity ratio of 1.08. Reckitt Benckiser Group has a one year low of $10.43 and a one year high of $14.15. The company has a 50-day moving average of $13.22 and a 200 day moving average of $12.95.
Reckitt Benckiser Group Company Profile
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
